Medical devices, healthcare technology and the business of care
DEVICE CATEGORY · PLS

Immunohistochemistry Assay, Antibody, Programmed Death-Ligand 1

The programmed death-ligand 1 (PD-L1) antibody is a qualitative immunohistochemical antibody intended to identify PD-L1 protein expression in human clinical tissue specimens. The PD-L1 antibody is indicated as an aid in identifying patients eligible for treatment with specific FDA approved therapeutic drugs or to assess PD-L1 expression level in patients who may respond particularly well to specific FDA approved therapeutic drugs.

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA supplementSep 21, 2026FDA
Agilent Technologies, Inc.PMA supplementSep 11, 2026FDA
Agilent Technologies, Inc.PMA supplementJul 1, 2026FDA
Agilent Technologies, Inc.PMA supplementMar 19, 2026FDA
Agilent Technologies, Inc.PMA supplementFeb 11, 2026FDA
Agilent Technologies, Inc.PMA supplementFeb 10, 2026FDA
Agilent Technologies, Inc.PMA supplementAug 4, 2025FDA
Agilent Technologies, Inc.PMA approvalOct 2, 2015FDA
Source information

Follow the FDA links to view the original records.

All device categories